Artrya vs Heartflow (2026)
Both analyze coronary CT angiography, but Heartflow's core product is physiology and Artrya's is a reading platform. Heartflow's FFRCT simulates the physiological significance of each lesion; it was first authorized in 2014 and validated against invasive FFR in the prospective HeartFlowNXT study, with the PRECISE randomized trial and large registries behind the platform. Its Case Analysts work each model, and the indications page states where the analysis was not evaluated. Artrya's Salix gives physicians an automated anatomy and plaque analysis they edit before reporting, cleared in 2025, with a fractional flow reserve module still in validation. If lesion level physiology is the decision, start with Heartflow. If you want your own physicians reading plaque and stenosis on a platform with a published contract figure, start with Artrya.
- You want your physicians reading in house: Salix returns an automated analysis in minutes, which the physician edits before reporting.
- You want test data with counts: K251837 reports standalone results on held out centers and a reader study of 103 patients across seven US centers.
- You want a price reference: an ASX filing puts a five hospital deployment at US$0.6 million over five years, plus a per scan plaque fee.
- Physiology is the decision: FFRCT estimates the physiological significance of each lesion, validated against invasive FFR in the prospective, multicenter HeartFlowNXT study.
- You want the evidence base: the PRECISE randomized trial, the ADVANCE registry and the DECIDE registry of about 22,000 patients.
- You want the limits stated: the indications page names the populations the analysis was not evaluated in, and trained Case Analysts work on each model.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Artrya and Heartflow are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Artrya | Heartflow |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | Not recorded | 2007 |
| Headquarters | Perth, Western Australia, Australia | Mountain View, California, United States |
| Website | artrya.com | heartflow.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Heartflow
-
Product / capability
Heartflow PCI Navigator entered commercial use outside of clinical trials, with The Valley Hospital becoming the first U.S. institution to deploy the software.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Artrya, listed on the ASX (AYA) and based in Perth, sells Salix, a cloud platform for reading coronary CT angiography at the point of care. Physicians start from an automated analysis, returned in minutes without an external reading team, and edit it before reporting. Machine learning handles centerline extraction, vessel labeling, lumen and wall segmentation and calcium scoring, and plaque is quantified from Hounsfield unit ranges, including low attenuation plaque, spotty calcification, positive remodeling and the napkin-ring sign.
Source: AI Health Index, September 2026
Heartflow created non-invasive coronary physiology from CT. Its Heartflow One platform analyzes a coronary CT angiogram a hospital has already acquired: Roadmap Analysis for stenosis, FFRCT Analysis for the physiological significance of each lesion, simulated from a 3D model of the coronary arteries, Plaque Analysis and plaque staging, and PCI Navigator for planning intervention, now in routine use at The Valley Hospital.
Source: AI Health Index, September 2026
Questions buyers ask
How do Artrya and Heartflow work with the EHR?
Artrya's announcement of its Tanner Health contract says Salix Coronary Anatomy was integrated into Tanner's PACS and electronic medical record and is in clinical use across its five hospitals; Northeast Georgia Health System and Cone Health are further customers. Salix reads DICOM from any CT scanner, and new modules such as Coronary Plaque switch on inside the same interface without a separate integration project.
Heartflow describes CT studies sent securely to it without manual export and results returned into both PACS and the electronic record, with a support team that deploys the software and integrates it with PACS, record and other hospital systems. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How are Artrya and Heartflow priced and sold?
Artrya's ASX announcement of its first US customer states a five year SaaS license for Salix Coronary Anatomy at a monthly subscription fee, valued at US$0.6 million over 60 months for Tanner Health's five hospitals and 30 practices, with a fee per scan added for Coronary Plaque and, once cleared, Coronary Flow. Further US customers are reported on the same subscription plus per scan structure.
Heartflow publishes reimbursement resources and a market access value dossier. The dossier records a Category I CPT pathway for AI plaque analysis of coronary CT, CMS payment for plaque analysis as a separate outpatient hospital service, a July 2025 EviCore coverage recommendation for Plaque Analysis, and states frankly that current reimbursement does not adequately pay for FFRCT. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How do Artrya and Heartflow handle patient data?
With Artrya, no retention period is given, and because the default instruction is not to put personal information into the product at all, it is unclear which document actually governs an identified coronary CT study. The same policy separately permits disclosure to a third party who may combine data to develop anonymized consumer insights, and lists advertising and marketing among its purposes, with no clinical carve out.
Heartflow's trust center names encryption at rest, access monitoring, audit logging, role based access control and backups, names Amazon Web Services as its infrastructure provider, and lists AI training data and bias, AI security and AI monitoring as categories a customer can ask about, with the underlying documents released on request. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Which settings and specialties do Artrya and Heartflow cover?
For Artrya, the cleared indication covers adjunctive analysis of CCTA for patients evaluated for known or suspected coronary disease and calcium scoring on non-contrast cardiac CT, on any CT scanner. The validation in K251837 spans seven US centers, four scanner makers, adults aged 23 to 84 and routine clinician readers.
With Heartflow, the intended use covers adults 22 and over with suspected coronary artery disease (the combined analysis) and clinically stable symptomatic patients (FFRCT), and FFRCT's performance was validated in patients who were candidates for invasive angiography, with CT acquired within 60 days of invasive FFR. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Heartflow's Plaque Analysis and Roadmap are cleared in the US but not in Europe, the UK, Australia, Canada or Japan, where only FFRCT and planning are available. Heartflow does not publish pricing, and its reimbursement pages describe what payers pay, not its own charge. Artrya's fractional flow reserve module is not yet cleared.